Search

everythinglearnresearchcommunity

for

Search:↓

People are discussing their reactions if PP405 fails in phase 3 trials, with some expressing skepticism and others holding onto hope for future treatments like GT20029 and Breezula. Many mention continuing with existing treatments like minoxidil and finasteride, while others express disappointment and consider alternative solutions.

Epristeride is a selective 5 alpha reductase type 2 inhibitor that may reduce scalp DHT similarly to finasteride, with potentially fewer side effects. It is suggested that combining epristeride with finasteride or dutasteride could enhance hair loss treatment effectiveness.

A user shared their positive experience with hair regrowth using minoxidil, hormone replacement therapy, and cyproterone acetate during their male-to-female transition. Another user discussed their successful hair transplant after transitioning and using finasteride, highlighting the challenges of hair loss and regrowth during transition.

User gained hair with topical minoxidil and finasteride, then experienced shedding after starting pyrilutamide. After 12 weeks, new hairs grew and existing hairs thickened, hoping for more improvement in a year.

The user had a failed hair transplant in 2018, didn't use medication, and experienced severe depression from further hair loss. They started treatment in 2022 with 0.5mg daily finasteride, 2.5mg oral minoxidil, 1ml daily topical minoxidil, and are considering low dose RU58841 and dermarolling.

A user discusses a topical prescription for hair regrowth containing Minoxidil, Finasteride, and Latanoprost, noting Latanoprost's side effect of promoting eyelash and eyebrow growth. Others share experiences and information about Latanoprost, highlighting its origins as a glaucoma drug and potential side effects.

A user shared their 11-year experience with spironolactone and nearly 5 years with finasteride for hair loss, recently adding oral minoxidil and stopping birth control. Various treatments were discussed, including organic options, checking for underlying health issues, considering dutasteride, and the potential role of progesterone in hair loss.

The conversation discusses using scalp antiandrogens like RU58841, pyrilutamide, or fluridil on the face to reduce sebum production, noting that clascoterone (winlevi) is an approved facial antiandrogen with underwhelming reviews.

A user reported less hair shedding using melatonin spray and is considering trying topical oxytocin or estrogel for hair growth, but is concerned about potential side effects like breast development. Topical oxytocin has been found to promote hair growth by increasing growth factors.

The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.

The user experienced side effects from finasteride and found improved mood and performance with DHT, but it worsened hair loss. They are considering options like TRT, HCG, and topical treatments like Saw Palmetto, but struggle with balancing hair preservation and functionality.

A 23-year-old man with hair loss, despite using dutasteride, oral minoxidil, and RU58841, is considering bicalutamide for regrowth but is concerned about feminization. Alternatives like topical estrogen, JXL069, and spironolactone are discussed, with suggestions to explore thyroid levels and other potential underlying conditions.

The user regrets stopping finasteride and minoxidil due to side effects but plans to resume treatment. They consider using finasteride every other day and continuing topical minoxidil to manage side effects while maintaining hair.

The Phase 2 trial for Pyrilutamide in the US, which started a year after the China trials, and inquiring about any available information on when it will finish. Treatments discussed include Minoxidil, Finasteride, and RU58841.

Finasteride and dutasteride are not considered safe during pregnancy, with some users suggesting caution and others sharing personal experiences of no issues. The general consensus is to avoid these medications during pregnancy to prevent any potential risks.

The conversation discusses a user's 3.5-month experience using pyrilutamide and minoxidil for hair loss, with some perceived improvement in the temples but potential recent regression. Another user suggests that maintaining the current hairline, even without improvement, is positive.

RU58841 is considered effective by some users, but finasteride and minoxidil are commonly used with varying dosages to manage side effects. Users report different experiences with treatments like pyrilutamide, fluridil, and RU58841, with some seeing results and others not.

The conversation discusses whether stemoxydine needs to be used for life for hair loss treatment. One user suggests that stemoxydine does not require lifelong use and can make hair exit the resting phase faster, but the benefits may be temporary.

Pyrilutamide is seen as effective for maintaining hair without regrowth, while Minoxidil is known for growing new hair but causes shedding of old hairs. There is a question if using Pyrilutamide would inhibit the hair regrowth effects of Minoxidil.

Pyrilutamide phase 3 results showed little to no significant hair regrowth, but may be sufficient for maintaining current hair density. The user is unsure due to lack of recent discussions on pyrilutamide.

The user is experiencing diffuse androgenic alopecia and is trying various treatments, including 5mg finasteride, loniten, and Formula 82D, which contains dutasteride, a steroid, and tretinoin. They report potential regrowth with Formula 82D, despite previous treatments being ineffective.

The user has not seen results from various hair loss treatments including finasteride, dutasteride, minoxidil, and others over several years and is considering adding RU58841 and starting hormone replacement therapy. They are also experiencing anxiety and contemplating moving to a more accepting environment for their nonbinary identity.

Pyrilutamide, a potentially effective hair loss treatment; other topical treatments like RU58841 and CB-03-01 that may have fewer side effects than Pyrilutamide; and the Phase 3 clinical trials of Pyrilutamide, which is likely to be approved by the FDA soon.

The conversation is about comparing the effectiveness of fluridil and clascoterone in preventing hair loss and inquiring about their use as standalone treatments. There is a question about the concentration of the fluridil brand for efficacy.

User shared 3-week progress using Pyrilutamide once a day for hair loss. Another user shared their 3-month progress with 0.25% concentration Pyrilutamide, experiencing rollback of 4 years in 3 months.

A user beginning a treatment of pyrilutamide for hair loss, which they plan on updating progress on every month.

High prolactin levels can cause hair loss, and finasteride may increase prolactin. Cabergoline or Vitamin B6 might lower prolactin, but combining them with finasteride requires caution.

HairCarePls shared their 5-month Dutasteride update, mentioning previous use of Finasteride with no results. They also use Spironolactone, Minoxidil, dermarolling, Ketoconazole shampoo, and Yaz contraception for hair loss treatment.

A 19-year-old transgender individual is experiencing worsening temple recession despite taking female hormones and 1.25mg finasteride. They are seeking advice on additional treatments to address hair loss.

PP405 might make minoxidil unnecessary, but finasteride or other 5AR inhibitors may still be needed. PP405 is expected to be expensive and not available until at least 2028, with limited information on its effectiveness.